Tenderwize
Retour à la recherche

Discount Contract for Cobicistat/Elvitegravir/Emtricitabin/Tenofovirdisoproxil (Stribild(R))

Techniker Krankenkasse·Hamburg, Germany·Deadline Feb 27, 2027 · 185 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-03 - Cobicistat/Elvitegravir/Emtricitabin/Tenofovirdisoproxil (Stribild(R))

20/100

Score d'opportunité

High riskLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

20 / 100

Complexité

30 / 100

Facteurs de risque

Patent expiry or loss of market exclusivity terminates the contract automatically. Uncertain timeline may affect supply...

No estimated volume or value; financial benefit cannot be quantified.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Weak opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Feb 2027
  • Supply of pharmaceutical product: Cobicistat/Elvitegravir/Emtricitabin/Tenofovirdisoproxil (Stribild(R))
  • Participation in Open House discount contract procedure under § 130c SGB V
Afficher le résumé complet

Open House procedure for discount contracts (Rabattverträge) for the drug combination Cobicistat/Elvitegravir/Emtricitabin/Tenofovirdisoproxil (Stribild(R)) with German health insurance companies. Eligible pharmaceutical entrepreneurs can join at any time during the contract period (01.03.2025 – 28.02.2027). No estimated value, award criteria, or procurement documents were provided in the analysis.

Risques

Patent expiry or loss of market exclusivity terminates the contract automatically. Uncertain timeline may affect supply...

No estimated volume or value; financial benefit cannot be quantified.

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur (pharmazeutischer Unternehmer) as per § 4 Abs. 18 AMG concerning the specific medicinal product.
  • Must have a valid marketing authorization for the product in Germany or be entitled to market it.

Eligibility

  • Must submit a self-declaration confirming eligibility and reliability (no criminal records, etc.).

Les exigences peuvent être incomplètes.

Acheteur

Localisation

Hamburg, DEU

Identifiant

992-80116-93

Activité

Health

Lots (1)

LOT-0001

Discount Contract for Cobicistat/Elvitegravir/Emtricitabin/Tenofovirdisoproxil (Stribild(R))

The TK aims to conclude discount contracts with all eligible pharmaceutical entrepreneurs for the drug combination Cobicistat/Elvitegravir/Emtricitabin/Tenofovirdisoproxil (Stribild(R)). No exclusivity, individual negotiations, or award criteria. Contract duration max 24 months from 01.03.2025 to 28.02.2027. Patent expiry may terminate contract earlier.

SuppliesEU fundedElectronic submission

Localisation

DE600, Germany

Durée

Feb 2025 - Feb 2027

Catégorie

Pharmaceutical products

Détails de la procédure

Date de publication
20 Jan 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
42252-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3